Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a study to determine if a certain drug, called telotristat ethyl (Xermelo®), can help
reduce the chance of blood pressure and heart rate variations (known as carcinoid crisis) in
individuals who have neuroendocrine tumors (also called carcinoid tumors). These
complications can be life-threatening for patients who already have to experience challenging
surgeries to remove their tumors. To determine if telotristat ethyl (Xermelo®) will help
reduce these complications during surgery, researchers will give the drug to study
participants before surgery.